xMedica

NCT04153292ClinicalTrials.gov

The ENCIRCLE Trial

SAPIEN M3 System Transcatheter Mitral Valve Replacement Via Transseptal Access

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects…

تدخّليةمطلوب 900 مشارك68 موقعاً6 دول

الفئات

القلب والأوعية الدموية100%

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Registered before enrolment beganFirst posted 2019-11-06; recorded start 2020-11-12
  • Has a defined primary outcomeA primary outcome measure is listed in the record
  • The primary outcome states a time frameThe primary outcome measure records a time frame
  • Participants are not randomly assignedAllocation is recorded as non-randomised
  • Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Open label (no blinding)Masking is recorded as none (open label)
  • An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Sponsor has 47 other studies in this databaseCounted from the lead sponsor named in the record (Edwards Lifesciences)
  • Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourMODERATE

A moderately rigorous design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Non-randomised allocation

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 68 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 900 participants (target), run at 68 sites, across 6 countries.

How this score is built
  • Enrolment29/40

    900 participants (target)

  • Site count21/25

    68 sites

  • Country count12/15

    6 countries

  • Planned duration10/10

    Planned over about 125 months

  • Sponsor scale6/10

    Edwards Lifesciences has led 47 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

This is a prospective single-arm, multicenter study.

الحالات

  • Mitral Regurgitation
  • Mitral Valve Insufficiency

الأهلية

الجنسالجميع
الأعمار18 Years – لا حد أقصى
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion Criteria: 1. 18 years of age or older 2. MR ≥ 3+ 3. NYHA functional class ≥ II 4. Per the Heart Team, commercially available surgical or transcatheter treatment options are deemed unsuitable due to clinical, anatomic or technical considerations. 5. Subject's heart failure management has been optimized based on subject characteristics and applicable guidelines, and stable for at least 30 days prior to enrollment. 6. The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. Exclusion Criteria: 1. Mitral/cardiac anatomy that would preclude appropriate delivery and deployment of the SAPIEN M3 dock or valve 2. Inappropriate anatomy for femoral introduction and delivery of the SAPIEN M3 dock and valve 3. Presence of any device that will contact or interfere with the SAPIEN M3 System during delivery or after implantation 4. Left ventricular ejection fraction \<25% 5. Severe right ventricular dysfunction 6. Need for aortic, tricuspid or pulmonic valve intervention within the next 12 months 7. History of heart transplant 8. Cardiac imaging evidence of intracardiac mass, thrombus or vegetation 9. Active bacterial endocarditis within 180 days of the procedure 10. Hemodynamic instability requiring inotropic or mechanical support within 30 days of the procedure 11. Myocardial infarction within 30 days of the procedure 12. Clinically significant untreated coronary artery disease requiring revascularization 13. Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of the procedure 14. Stroke or transient ischemic attack within 90 days of the procedure 15. Irreversible, severe pulmonary hypertension 16. Chronic obstructive pulmonary disease requiring home oxygen therapy or chronic outpatient oral steroid use 17. Renal insufficiency or receiving renal replacement therapy 18. Liver disease 19. Planned surgery within the next 12 months 20. Inability to tolerate or a medical condition precluding treatment with antithrombotic therapy, including heparin administration during the procedure 21. Active infection requiring current antibiotic therapy 22. Active SARS-CoV-2 infection (Coronavirus-19 \[COVID-19\]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments 23. Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy or hypercoagulable states 24. Refusal of blood products 25. Female who is pregnant or lactating 26. Estimated life expectancy \<12 months due to non-cardiac conditions 27. Participating in another investigational drug or device study that has not reached its primary endpoint 28. Subject considered to be part of a vulnerable population

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

نوع الدراسةتدخّلية
المرحلةغير منطبق
التخصيصغير معشّاة
نموذج التدخّلSINGLE_GROUP
الغرض الأساسيTREATMENT
التعميةNONE (0)
التجنيدمطلوب 900 مشارك

الجهة الراعية والمتعاونون

  • Edwards Lifesciences الجهة الراعية

الأذرع والتدخلات

  • TMVR - Main CohortEXPERIMENTAL

    Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR).

  • TMVR - Failed TEER RegistryEXPERIMENTAL

    Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR.

  • TMVR - MAC RegistryEXPERIMENTAL

    Subjects with mitral annular calcification (MAC) will have TMVR.

التدخلات

  • جهاز SAPIEN M3 valve and dock

    During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Non-hierarchical composite of death and heart failure rehospitalization

    Number of subjects with death and/or heart failure rehospitalization

    الإطار الزمني 1 year

  2. مقياس النتيجة الثانوي

    Improvement in NYHA functional class compared to baseline

    New York Heart Association (NYHA) functional classification of heart failure is based on how much a patient is limited during physical activity. The rating ranges from I-IV. I = no limitations of physical activity; II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath; IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest.

    الإطار الزمني 1 year

  3. مقياس النتيجة الثانوي

    Improvement in KCCQ Overall Score compared to baseline

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    الإطار الزمني 1 year

  4. مقياس النتيجة الثانوي

    Improvement in MR compared to baseline

    Number of subjects with improved MR compared to baseline

    الإطار الزمني 1 year

  5. مقياس النتيجة الثانوي

    Decrease in LVEDVi compared to baseline

    Number of subjects with decreased left ventricular end-diastolic volume index (LVEDVi) compared to baseline

    الإطار الزمني 1 year

التواريخ

تاريخ البدء12 نوفمبر 2020 (فعلي)
الإتمام الأولي28 فبراير 2027 (تقديري)
الإتمام28 فبراير 2031 (تقديري)
أول نشر6 نوفمبر 2019 (فعلي)
آخر تحديث25 فبراير 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةفبراير 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

3 مواقع قيد التجنيد

Australia

المنشأةالمدينةالولاية أو المنطقةالحالة
Royal Prince Alfred HospitalCamperdownنشط، دون تجنيد
The Prince Charles HospitalChermsideQueenslandنشط، دون تجنيد

Canada

المنشأةالمدينةالولاية أو المنطقةالحالة
Laval UniversityQuébecQuebecقيد التجنيد
St. Michael'sTorontoقيد التجنيد
St. PaulsVancouverقيد التجنيد

Israel

المنشأةالمدينةالولاية أو المنطقةالحالة
Shaare Zedek Medical CenterJerusalemمسحوب
Rabin Medical CenterPetah Tikvaنشط، دون تجنيد
Sheba Medical CenterRamat Ganمسحوب

Netherlands

المنشأةالمدينةالولاية أو المنطقةالحالة
Leiden University Medical CenterLeidenنشط، دون تجنيد
Rotterdam Erasmus MCRotterdamنشط، دون تجنيد

United Kingdom

المنشأةالمدينةالولاية أو المنطقةالحالة
Saint Thomas HospitalLondonنشط، دون تجنيد
Saint Bartholomew's Medical CenterLondonنشط، دون تجنيد

United States

المنشأةالمدينةالولاية أو المنطقةالحالة
Piedmont HealthcareAtlantaGeorgiaنشط، دون تجنيد
Emory UniversityAtlantaGeorgiaنشط، دون تجنيد
Austin HeartAustinTexasنشط، دون تجنيد
Medstar Union Memorial HospitalBaltimoreMarylandنشط، دون تجنيد
Our Lady of the Lake Regional Medical CenterBaton RougeLouisianaنشط، دون تجنيد
Brigham & Women'sBostonMassachusettsمسحوب
Massachusetts General HospitalBostonMassachusettsنشط، دون تجنيد
University of BuffaloBuffaloNew Yorkنشط، دون تجنيد
Novant Health and Vascular InstituteCharlotteNorth Carolinaنشط، دون تجنيد
Carolinas Medical CenterCharlotteNorth Carolinaمسحوب
Rush University Medical CenterChicagoIllinoisمسحوب
The Christ HospitalCincinnatiOhioنشط، دون تجنيد
Cleveland Clinic FoundationClevelandOhioنشط، دون تجنيد
Mount Carmel East HospitalColumbusOhioنشط، دون تجنيد
Delray Medical CenterDelray BeachFloridaمسحوب
Henry FordDetroitMichiganنشط، دون تجنيد
Cardiac & Vascular Institute FoundationGainesvilleFloridaنشط، دون تجنيد
Northshore University Health SystemGlenviewIllinoisنشط، دون تجنيد
UT Memorial HermannHoustonTexasنشط، دون تجنيد
HCA Houston Healthcare Medical (SCRI)HoustonTexasنشط، دون تجنيد
Heart Center HospitalHuntsvilleAlabamaنشط، دون تجنيد
St. Vincent Heart Center of IndianaIndianapolisIndianaمسحوب
Ascension St. Vincent's HospitalJacksonvilleFloridaنشط، دون تجنيد
University of KansasKansas CityKansasنشط، دون تجنيد
Saint Luke's Kansas CityKansas CityMissouriنشط، دون تجنيد
Scripps HealthLa JollaCaliforniaنشط، دون تجنيد
Dartmouth-Hitchcock Medical CenterLebanonNew Hampshireنشط، دون تجنيد
Good Samaritan HospitalLos AngelesCaliforniaنشط، دون تجنيد
Kaiser Sunset LALos AngelesCaliforniaنشط، دون تجنيد
Cedars-Sinai Medical CenterLos AngelesCaliforniaنشط، دون تجنيد
UC Health Northern Colorado (Medical Center of the Rockies)LovelandColoradoنشط، دون تجنيد
University of WisconsinMadisonWisconsinمسحوب
UPMC Heart and Vascular InstituteMechanicsburgPennsylvaniaنشط، دون تجنيد
Minneapolis HeartMinneapolisMinnesotaمسحوب
St. Patrick HospitalMissoulaMontanaمسحوب
Morristown Medical CenterMorristownNew Jerseyمسحوب
Intermountain Medical CenterMurrayUtahنشط، دون تجنيد
Naples Community HospitalNaplesFloridaنشط، دون تجنيد

يُدرَج 18 موقعاً إضافياً في سجل السجل.

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

لم تُسجَّل أي تغييرات منذ أن أدرجنا هذا السجل لأول مرة.

يُسجَّل تغيير في كل مرة تحدّث فيها الجهة الراعية سجل السجل. تظهر هنا الحالة والتواريخ والتجنيد والمواقع كلما تغيّرت.

السجل: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT04153292